Skip to main content
. 2024 Jul 8;26(12):2352–2363. doi: 10.1093/neuonc/noae121

Figure 3.

Figure 3.

Effects of selumetinib on Neurocognitive function, growth parameter, and café-au-lait spots. (A) Proportion of children (n = 54) and adult (n = 30) patients with normal (blue), borderline (orange), or intellectual disability (ID; red) at baseline and cycle 12 according to VCI, PRI, WMI, PSI, and FSIQ scores. (B) Cognitive functioning ratings of 44 patients at baseline, cycle 12, and cycle 26. Mean ± S.E. *P < .05 versus baseline. *P < .05 versus baseline. (C) Standard deviation (SD) scores of heights and growth velocity of 37 prepubertal patients at baseline, cycle 12, and cycle 26. Mean ± S.D. *P < .05 versus baseline. (D) Representative images of patients who showed improvements in café-au-lait spots. Intensity score of Café au lait spots Mean ± S.D. *P < .05 versus baseline. VCI, verbal comprehension index; PRI, perceptual reasoning index; WMI, working memory index; PSI, processing speed index; FSIQ, Full-Scale IQ.